Request Demo

Last update 23 Jan 2025

Leukonychia Totalis

Last update 23 Jan 2025

Basic Info

Synonyms

Hereditary white nails, Leuconychia totalis, Leukonychia totalis

+ [9]

Introduction

A rare nail anomaly disorder characterised by complete white discolouration of the nails. Patients typically present white, chalky nails as an isolated finding, although other cutaneous or systemic manifestations could also be present. There is evidence the disease can be caused by homozygous or heterozygous mutation in the PLCD1 gene on chromosome 3p22-p21.3.

Drugs associated with Leukonychia Totalis

Cyclosporine

Target

CaN

Mechanism

CaN inhibitors

Active Org.

Novartis Pharmaceuticals KK [+27]

Originator Org.

Novartis Pharma AG

Active Indication

Conjunctivitis, Allergic [+45]

Inactive Indication

Acute Erythroblastic Leukemia [+107]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date14 Nov 1983

Clinical Trials associated with Leukonychia Totalis

NCT05613660

/ CompletedNot ApplicableIIT

A Proof of Science Clinical Study With Randomized, Four Arm, Comparative, Single-Blind, Within the Arm - Dose-Response Study to Evaluate the Safety, Efficacy of Different Collagen Peptide Containing Test Treatments in Adult Human Subjects

A proof of science clinical study with randomized, four-arm, comparative, single-blind, within the arm - Dose-Response Study to evaluate the safety and efficacy of different collagen peptide-containing test treatments in adult human subjects.
The dose-response will be evaluated for the effectiveness of each test treatment in three different dosages that is 2.5 g Versus 5 g Versus 10 g.
22 subjects will be enrolled per dose per test treatment to complete 20 subjects per dose per test treatment.

Start Date11 Jan 2023

Sponsor / Collaborator-

RBR-739987q

/ Not yet recruitingNot ApplicableIIT

Evaluation of nail physiology in elderly women supplemented with hydrolyzed oral collagen: a randomized, double-blind, placebo-controlled clinical trial

Start Date12 May 2022

Sponsor / Collaborator-

NCT04249128

/ CompletedPhase 3

The Derm Aid Study

A 90 day eight arm virtual interventional study looking at the impact of various supplement formulations for improves in hair, skin & nail health via self report, and dermatology assessment via remote dermatologist assessment.

Start Date15 Jan 2020

Sponsor / Collaborator

ProofPilot, Inc.Startup

[+1]

100 Clinical Results associated with Leukonychia Totalis

100 Translational Medicine associated with Leukonychia Totalis

0 Patents (Medical) associated with Leukonychia Totalis

185

Literatures (Medical) associated with Leukonychia Totalis

31 Dec 2024·Journal of Dermatological Treatment

Onychopapilloma: a single medical center experience in Southern Taiwan

Article

Author: Chang, Yung-Wei ; Lin, Shang-Hung ; Lai, Po-Ta

Background: Onychopapilloma is an uncommon benign tumor of the nail bed and the distal matrix. Objectives: We aimed to investigate the clinical and pathological features of onychopapilloma in Taiwan.Materials and methods: We conducted a retrospective analysis of 12 patients with histopathologically proven onychopapilloma in a medical center in southern Taiwan from 2017 to 2023. Results: This case series consisted of 5 men and 7 women aged 29 to 38, with a mean age of 41.25 years. The clinical features were as follows: distal subungual hyperkeratosis (100%), longitudinal erythronychia (50%), longitudinal leukonychia (50 %), distal onycholysis (41%), and distal nail plate fissuring (41%). The duration of the disease varied greatly, ranging from 1 month to several years. Most patients were asymptomatic (58%), while some presented tenderness (41%). Fingernail involvement was more prevalent than toe involvement, with the thumb being the most commonly affected site. Most of the patients presented with a solitary onychopapilloma. None of the seven patients who underwent surgery and were available for follow-up experienced recurrence.Conclusions: This study highlights that longitudinal erythronychia and leukonychia emerged as the predominant clinical presentations of onychopapilloma. Furthermore, our findings suggest that surgical excision appears to be an effective method for onychopapilloma.

01 Sep 2024·DIGITAL HEALTH

Artificial intelligence-enabled non-invasive ubiquitous anemia screening: The HEMO-AI pilot study on pediatric population

Article

Author: Gordon, Daniel ; Hoffman, Jason ; Gamrasni, Keren ; Barlev, Yotam ; Shpiegel, Ronen ; Koren, Ariel ; Lee, Hannah ; Patel, Shwetak ; Landau, Tamar ; Lahad, Avishai ; Levine, Alex ; Levin, Carina ; Liu, Xin ; Naor, Osnat ; Chayen, Gilad ; Brandwein, Michael

Objective Determine whether data collected from a smartphone camera can be used to detect anemia in a pediatric population. Methods HEMO-AI (Hemoglobin Easy Measurement by Optical Artificial Intelligence), a clinical study carried out from December 2020 to February 2023, recruited patients from the Pediatric Emergency Department, Pediatric Inpatient Department and Pediatric Hematology Unit of the Haemek Medical Center, Afula, Israel. A population-based sample of 823 patients aged 6 months to 18 years who had undergone a venous blood draw for a complete blood count since being admitted to the hospital were enrolled. Patients with total leukonychia, nailbed darkening or discoloration due to medication, nail clubbing, clinically indicated jaundice, subungual hematoma, nailbed lacerations, avulsion injuries, or nail polish applied on fingernails were not eligible for study recruitment. Video and images of the patients’ hand placed in a collection chamber were collected using a smartphone camera. Results 823 samples, 531 from a 12.2 megapixel camera and 256 from a 12.2 megapixel camera, were collected. 26 samples were excluded by the study coordinator for irregularities. 97% of fingernails and 68% of skin samples were successfully identified by a post-trained machine learning model. Separate models built to detect anemia using images taken from the Pixel 3 had an average precision of 0.64 and an average recall of 0.4, whereas models built using the Pixel 6 had an average precision of 0.8 and an average recall of 0.84. Further supplementation of training data with synthetic data boosted the precision of the latter to 0.84 and the average recall to 0.87. Conclusions This study lays the groundwork for the future evolution of non-invasive, pain-free, and accessible anemia screening tools tailored specifically for pediatric patients. It identifies important sample collection parameters and design, provides critical algorithms for the pre-processing of fingernail data, and reports an initial capability to detect anemia with 87% sensitivity and 84% specificity. Trial Registration Prospectively registered on www.clinicaltrials.gov (Identifier: NCT04573244) on 15 September 2020, prior to subject recruitment.

19 Apr 2024·Cureus

Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series

Article

Author: Mukit, Fabliha A ; Patel, Akash B ; Fleming, James C ; Mukit, Fabliha A ; Manley, Andrew ; Laplant, Jacquelyn F ; Hashemi, Marium ; Fowler, Brian T

As the use of teprotumumab for thyroid eye disease (TED) becomes more prolific, there remains a scarcity of literature regarding the associated side effects and adverse events of teprotumumab use. The authors present a single-center retrospective, observational case review of TED patients who received at least a single dose of teprotumumab infusion at the oculofacial plastic surgery service between February 2020 and July 2023. The most predominant recollected side effects were fatigue, brittle nails, dry eye symptoms, hair loss, muscle spasms, and dry mouth. Significant adverse events were limited to two cases of a blood clot and a single case of pulmonary embolism. This is the first retrospective study of patient-reported side effects and adverse events experienced by a cohort of teprotumumab users.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Leukonychia Totalis

Basic Info

Related

Analysis